144 related articles for article (PubMed ID: 36004532)
1. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
Lähteenvuo M; Luykx JJ; Taipale H; Mittendorfer-Rutz E; Tanskanen A; Batalla A; Tiihonen J
Br J Psychiatry; 2022 Dec; 221(6):758-765. PubMed ID: 36004532
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
3. Morbidity and mortality in schizophrenia with comorbid substance use disorders.
Lähteenvuo M; Batalla A; Luykx JJ; Mittendorfer-Rutz E; Tanskanen A; Tiihonen J; Taipale H
Acta Psychiatr Scand; 2021 Jul; 144(1):42-49. PubMed ID: 33650123
[TBL] [Abstract][Full Text] [Related]
4. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.
Luykx JJ; Stam N; Tanskanen A; Tiihonen J; Taipale H
Br J Psychiatry; 2020 Sep; 217(3):498-505. PubMed ID: 31910911
[TBL] [Abstract][Full Text] [Related]
5. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review.
Arranz B; Garriga M; García-Rizo C; San L
Eur Neuropsychopharmacol; 2018 Feb; 28(2):227-242. PubMed ID: 29273271
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
7. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
Taipale H; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences.
Taipale H; Puranen A; Mittendorfer-Rutz E; Tiihonen J; Tanskanen A; Cervenka S; Lähteenvuo M
Nord J Psychiatry; 2021 Jul; 75(5):315-322. PubMed ID: 33331804
[TBL] [Abstract][Full Text] [Related]
10. Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis.
Rafizadeh R; Danilewitz M; Bousman CA; Mathew N; White RF; Bahji A; Honer WG; Schütz CG
J Psychopharmacol; 2023 Feb; 37(2):135-143. PubMed ID: 36507548
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
12. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients.
Hartikainen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
JAMA Psychiatry; 2023 Jan; 80(1):31-39. PubMed ID: 36383348
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.
Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
Eur Neuropsychopharmacol; 2022 Jun; 59():36-44. PubMed ID: 35550204
[TBL] [Abstract][Full Text] [Related]
14. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
Taipale H; Schneider-Thoma J; Pinzón-Espinosa J; Radua J; Efthimiou O; Vinkers CH; Mittendorfer-Rutz E; Cardoner N; Pintor L; Tanskanen A; Tomlinson A; Fusar-Poli P; Cipriani A; Vieta E; Leucht S; Tiihonen J; Luykx JJ
JAMA Psychiatry; 2022 Mar; 79(3):210-218. PubMed ID: 35080618
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study.
Lähteenvuo M; Paljärvi T; Tanskanen A; Taipale H; Tiihonen J
Br J Psychiatry; 2023 Oct; 223(4):456-464. PubMed ID: 37395140
[TBL] [Abstract][Full Text] [Related]
16. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.
San L; Arranz B; Martinez-Raga J
Eur Addict Res; 2007; 13(4):230-43. PubMed ID: 17851245
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic medications and the progression of upper respiratory infection to pneumonia in patients with schizophrenia.
Chang CK; Chen PH; Pan CH; Su SS; Tsai SY; Chen CC; Kuo CJ
Schizophr Res; 2020 Aug; 222():327-334. PubMed ID: 32507380
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts.
Taipale H; Lieslehto J; Lähteenvuo M; Hamina A; Tanskanen A; Mittendorfer-Rutz E; Paljärvi T; Solmi M; Cipriani A; Correll CU; Tiihonen J
World Psychiatry; 2024 Jun; 23(2):276-284. PubMed ID: 38727044
[TBL] [Abstract][Full Text] [Related]
20. Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
Patel R; Chan KMY; Palmer EOC; Valko M; Guruswamy G; Ker S; Batra G; Rentería ME; Kollins SH
Schizophr Res; 2023 Oct; 260():191-197. PubMed ID: 37683509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
